Table 3.
Factors associated with MetS by gender.
| Q1 | Q2 | Q3 | Q4 | |
|---|---|---|---|---|
| Men | ||||
| GGT (U/L) | ≤20 | 21–29 | 30–43 | ≥44 |
| Cases/subjects at risk | 64/1,178 | 151/1,213 | 261/1,167 | 465/1,206 |
| OR (95% CI: lower–upper) | 1.00 | 1.40 (1.09–1.96) | 2.09 (1.50–2.91) | 3.50 (2.50–4.91) |
| ALT (U/L) | ≤19 | 20–27 | 28–38 | ≥39 |
| Cases/subjects at risk | 98/1,191 | 176/1,201 | 242/1,188 | 425/1,184 |
| OR (95% CI: lower–upper) | 1.00 | 1.23 (0.90–1.66) | 1.43 (1.05–1.95) | 1.81 (1.28–2.55) |
| AST (U/L) | ≤24 | 25–30 | 31–36 | ≥37 |
| Cases/subjects at risk | 129/1,214 | 188/1,294 | 222/1,145 | 402/1,111 |
| OR (95% CI: lower–upper) | 1.00 | 1.09 (0.82–1.45) | 1.07 (0.80–1.43) | 1.62 (1.19–2.20) |
| ALP (U/L) | ≤52 | 53–61 | 62–71 | ≥72 |
| Cases/subjects at risk | 198/1,288 | 217/1,106 | 244/1,202 | 282/1,168 |
| OR (95% CI: lower–upper) | 1.00 | 1.24 (0.96–1.61) | 1.29 (0.99–1.66) | 1.48 (1.16–1.90) |
| Women | ||||
| GGT (U/L) | ≤13 | 14–17 | 18–22 | ≥23 |
| Cases/subjects at risk | 22/1,843 | 44/1,386 | 100/1,151 | 310/1,409 |
| OR (95% CI: lower–upper) | 1.00 | 1.80 (1.04–3.10) | 3.49 (2.11–5.78) | 5.61 (3.41–9.23) |
| ALT (U/L) | ≤13 | 14–18 | 19–23 | ≥24 |
| Cases/subjects at risk | 27/1,480 | 64/1,624 | 98/1,248 | 287/1,437 |
| OR (95% CI: lower–upper) | 1.00 | 1.30 (0.79–2.13) | 1.44 (0.88–2.35) | 1.95 (1.19–3.21) |
| AST (U/L) | ≤22 | 23–26 | 27–31 | ≥32 |
| Cases/subjects at risk | 36/1,451 | 80/1,494 | 110/1,434 | 250/1,410 |
| OR (95% CI: lower–upper) | 1.00 | 1.62 (1.04–2.54) | 1.33 (0.85–2.07) | 2.01 (1.29–3.15) |
| ALP (U/L) | ≤42 | 43–51 | 52–63 | ≥64 |
| Cases/subjects at risk | 43/1,556 | 66/1,352 | 141/1,519 | 226/1,362 |
Abbreviations: MetS = metabolic syndrome; GGT = gamma-glutamyl transferase; ALT = alanine aminotransferase; AST = aspartate aminotransferase; ALP = alkaline phosphatase; OR = odds ratio; CI = confidence interval.